The risks of medical treatment of prolactinoma |
| |
| Authors: | Frederic Castinetti Frederique Albarel Vincent Amodru Thomas Cuny Henry Dufour Thomas Graillon Isabelle Morange Thierry Brue |
| |
| Affiliation: | 1. Service d’endocrinologie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France;2. Service de neurochirurgie, hôpital de la Timone, Timone, France;3. Aix Marseille université, centre de références maladies rares HYPO, Assistance Publique-Hôpitaux de Marseille, Marseille, France;2. Department of endocrine surgery, Hôpital Lyon Sud, 165, rue du grand Revoyet, 69495 Pierre-Bénite, France;3. Inserm U1290, Research on Healthcare Performance Lab (RESHAPE), Université Claude-Bernard Lyon 1, domaine Rockefeller, 8, avenue Rockefeller, 69003 Lyon, France;1. Centre de référence des maladies rares du calcium et du phosphore, centre de référence des maladies rénales rares, filières de santé maladies rares OSCAR, ORKID et ERKNet, service de néphrologie rhumatologie et dermatologie pédiatriques, hôpital femme mère enfant, Bron, France;2. INSERM 1033, prévention des maladies osseuses, Lyon, France;3. Service de néphrologie pédiatrique, CHU de Nice, hôpital Archet, Nice, France;4. Service d’exploration fonctionnelle rénale, centre de référence des maladies rares du calcium et du phosphore, centre de référence des maladies rénales rares, filières de santé maladies rares OSCAR et ORKID, département de néphrologie, hôpital Edouard-Herriot, Lyon, France;5. Faculté de Médecine Lyon Est, Université de Lyon, Lyon, France;1. Department of Endocrinology, Diabetes and Metabolic Diseases, Rouen University Hospital, Rouen, France;2. Department of Endocrinology, Diabetes and Metabolic Diseases, Hôpital de la Cavale Blanche, Brest, France;3. Department of Endocrinology, Diabetes and Nutrition, and PériTox, UMR-I 01 INERIS, University Picardie Jules Verne (UPJV), Amiens, France;1. Division of Endocrinology, Diabetes and Metabolism, Indiana University School of Medicine, Indianapolis, Indiana;2. Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana;3. Division of Endocrinology Diabetes and Metabolism, Mayo Clinic, Rochester, Minnesota;1. Department of Endocrinology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain;2. Department of Radiation Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain;3. Department of Nuclear Medicine, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain;4. Department of Neurosurgery, Hospital Universitario, Ramón y Cajal, Madrid, Spain;5. Department of Pathology, Hospital Universitario, Ramón y Cajal, Madrid, Spain |
| |
| Abstract: | First-line treatment of prolactinoma is usually medical, based on dopamine agonists receptors, mainly cabergoline. The classical side-effects of cabergoline (low blood pressure and nausea) have been well known since it was first introduced. Other side-effects, however, are more controversial or simply less frequent, but need to be considered during monitoring. This review will focus on these side-effects: cardiac valvular fibrosis, pleural, pericardial and retroperitoneal fibrosis, addictive/compulsive behaviors, and risks secondary to significantly decreased tumor volume. We will also describe how such side-effects should be monitored and managed. In our opinion, the low prevalence of these side-effects should not cast doubt on the role of cabergoline in the therapeutic algorithm of prolactinoma. |
| |
| Keywords: | Prolactinoma Transsphenoidal surgery Cabergoline Cardiac valvular fibrosis Addiction Prolactinome Chirurgie transsphénoïdale Cabergoline Valvulopathie Addiction |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
